You can also use the SingleCare app to show your pharmacist your card
[9] [10] The American Society of Anesthesiologists (ASA) and other medical societies have issued guidance on this topic, with updated recommendations in 2024 that move away from blanket cessation toward a more individualized, risk-stratified approach
GLP-1 plotters use published pharmacokinetic data from clinical trials and FDA documentation
Non-ischemic cardiomyopathies, which exclude coronary artery disease or ischemic injury, can be classified based on morphology, function, and genomics
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test can help provide context about your individual predispositions in peptide metabolism and response pathways
Nothing on this website should be interpreted as medical advice, health advice, or as a recommendation for the use of any product in humans or animals